Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 6/20 | 0.42 |
| ▸ | TACR1 | P25103 | 6/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7187047 | 0.91 | KMT2A (0.48) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6540815 | 0.87 | TACR1 (0.55) | MEN1KMT2ATACR1 | |
| SCHEMBL6541677 | 0.81 | TACR1 (0.44) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL7205922 | 0.81 | HTT (0.55) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL7205927 | 0.81 | HTT (0.55) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6541329 | 0.81 | HTT (0.55) | MEN1KMT2AALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL6541598 | 0.81 | TACR1 (0.51) | MEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL6540480 | 0.80 | TACR1 (0.50) | MEN1KMT2AALDH1A1TSHRTACR1 | |
| SCHEMBL6540941 | 0.80 | TACR1 (0.56) | MEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL6541642 | 0.79 | TACR1 (0.57) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | MEN1 629/4885KMT2A 2124/4885ALDH1A1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.